The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-06-06
DOI
10.3389/fonc.2019.00447
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR
- (2018) Hidejiro Torigoe et al. CARCINOGENESIS
- LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling
- (2018) Qungen Xiao et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma
- (2018) Feng Mao et al. Oncogenesis
- LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial–mesenchymal transition
- (2018) Wei Li et al. BIOSCIENCE REPORTS
- Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
- (2018) Huimin Hu et al. CELL
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses
- (2017) Timothy Cloughesy et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
- (2017) Patrick Y Wen et al. NEURO-ONCOLOGY
- Cyst Fluid From Cystic, Malignant Brain Tumors: A Reservoir of Nutrients, Including Growth Factor-Like Nutrients, for Tumor Cells
- (2017) Daniel Dahlberg et al. NEUROSURGERY
- Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma
- (2017) Cecilia Ranhem et al. PLoS One
- Cardiac hypertrophy and decreased high-density lipoprotein cholesterol in Lrig3-deficient mice
- (2016) Martin Hellström et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
- (2016) L. Erdem-Eraslan et al. CANCER RESEARCH
- PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition
- (2016) Hua-Fu Zhao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Progress in glioma diagnosis, classification and treatment
- (2016) Patrick Y. Wen et al. Nature Reviews Neurology
- Lrig1 is a positive prognostic marker in hepatocellular carcinoma
- (2016) Bo Yang et al. OncoTargets and Therapy
- High levels of c-Met is associated with poor prognosis in glioblastoma
- (2015) Stine Asferg Petterson et al. JOURNAL OF NEURO-ONCOLOGY
- LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor
- (2015) Dongsheng Guo et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Survival and low-grade glioma: the emergence of genetic information
- (2015) Elizabeth B. Claus et al. Neurosurgical Focus
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET for glioma therapy
- (2014) Ahmed J. Awad et al. Neurosurgical Focus
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
- (2014) Christiane R. Maroun et al. PHARMACOLOGY & THERAPEUTICS
- Soluble LRIG2 Ectodomain Is Released from Glioblastoma Cells and Promotes the Proliferation and Inhibits the Apoptosis of Glioblastoma Cells In Vitro and In Vivo in a Similar Manner to the Full-Length LRIG2
- (2014) Qungen Xiao et al. PLoS One
- EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells
- (2014) Kiran Kumar Velpula et al. Translational Oncology
- The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme
- (2013) O. F. Olmez et al. Clinical & Translational Oncology
- Leucine-rich Repeat and Immunoglobulin Domain-containing Protein-1 (Lrig1) Negative Regulatory Action toward ErbB Receptor Tyrosine Kinases Is Opposed by Leucine-rich Repeat and Immunoglobulin Domain-containing Protein 3 (Lrig3)
- (2013) Hanine Rafidi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status
- (2013) Mikael Johansson et al. NEURO-ONCOLOGY
- Ionizing Radiation in Glioblastoma Initiating Cells
- (2013) Maricruz Rivera et al. Frontiers in Oncology
- METGain in Diffuse Astrocytomas is Associated with Poorer Outcome
- (2012) Daniela Pierscianek et al. BRAIN PATHOLOGY
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression
- (2012) Ji Yuan et al. HUMAN PATHOLOGY
- Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
- (2012) Shota Tanaka et al. Nature Reviews Clinical Oncology
- Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation
- (2012) RUIFAN XIE et al. ONCOLOGY REPORTS
- Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
- (2011) Matija Snuderl et al. CANCER CELL
- Effect of over-expressed LRIG3 on cell cycle and survival of glioma cells
- (2011) Hongkuan Yang et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme
- (2011) H J Jun et al. ONCOGENE
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
- (2011) Q. Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype
- (2011) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
- (2010) E. G. Van Meir et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1
- (2010) Wei Yi et al. EXPERIMENTAL CELL RESEARCH
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Cross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear
- (2008) V. E. Abraira et al. DEVELOPMENT
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started